Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? - Liu, Bingwen; Li, Min; Zhou, Zhiguang; Guan, Xuan; Xiang, Yufei (Journal of autoimmunity, 2020)
Keywords: Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Betacoronavirus - pathogenicity; Coronavirus disease 2019; Coronavirus Infections - pathology; COVID-19; Cytokine release syndrome; Cytokine Release Syndrome - therapy; Humans; Immunomodulation - drug effects; Interleukin-6; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - blood; Pandemics; Pneumonia, Viral - pathology; SARS-CoV-2; Severe Acute Respiratory Syndrome - pathology; Tocilizumab; Cytokine release syndrome; Coronavirus disease 2019; Tocilizumab; Interleukin-6